Compass Therapeutics Inc. (CMPX), a clinical-stage, oncology-focused biopharmaceutical company, has a clinical trial catalyst to watch this quarter.
The company's lead drug candidate is Tovecimig (formerly CTX-009), a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A (VEGF-A) signaling pathways. Both of these are critical to angiogenesis and tumor vascularization.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com